VCM
ZVRA icon

Versant Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Versant Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$516 Hold
36
– – ﹤0.01% 2691
2026
Q1 		$336 Buy
+36
New +$325 ﹤0.01% 2742

Other funds holding ZVRA

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
IA
IFG Advisors St. Louis, Missouri $725M AUM 27.52% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CSB
City State Bank Norwalk, Iowa $436M AUM 32.32% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Versant Capital Management's ZVRA Position: Q2 2026 in Review

Versant Capital Management held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 36 shares worth $516. The position accounts for ﹤0.01% of the portfolio, ranked #2691.

Versant Capital Management first reported a position in ZVRA in Q1 2026 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Versant Capital Management held 36 shares of Zevra Therapeutics worth $516 as of Q2 2026.
  • Versant Capital Management left its Zevra Therapeutics share count unchanged in Q2 2026.
  • Zevra Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2691 holding.
  • Versant Capital Management first reported a position in Zevra Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 15 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.